GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quest PharmaTech Inc (TSXV:QPT) » Definitions » ROIC %

Quest PharmaTech (TSXV:QPT) ROIC % : -0.91% (As of Oct. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Quest PharmaTech ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Quest PharmaTech's annualized return on invested capital (ROIC %) for the quarter that ended in Oct. 2023 was -0.91%.

As of today (2024-05-22), Quest PharmaTech's WACC % is 1.00%. Quest PharmaTech's ROIC % is -1.51% (calculated using TTM income statement data). Quest PharmaTech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Quest PharmaTech ROIC % Historical Data

The historical data trend for Quest PharmaTech's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest PharmaTech ROIC % Chart

Quest PharmaTech Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -87.94 -98.41 -1.11 -0.59 -0.95

Quest PharmaTech Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.67 -1.00 -0.96 -3.25 -0.91

Competitive Comparison of Quest PharmaTech's ROIC %

For the Biotechnology subindustry, Quest PharmaTech's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest PharmaTech's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quest PharmaTech's ROIC % distribution charts can be found below:

* The bar in red indicates where Quest PharmaTech's ROIC % falls into.



Quest PharmaTech ROIC % Calculation

Quest PharmaTech's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jan. 2023 is calculated as:

ROIC % (A: Jan. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jan. 2022 ) + Invested Capital (A: Jan. 2023 ))/ count )
=-0.834 * ( 1 - 0% )/( (91.255 + 84.736)/ 2 )
=-0.834/87.9955
=-0.95 %

where

Quest PharmaTech's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Oct. 2023 is calculated as:

ROIC % (Q: Oct. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jul. 2023 ) + Invested Capital (Q: Oct. 2023 ))/ count )
=-0.628 * ( 1 - 0% )/( (70.392 + 68.033)/ 2 )
=-0.628/69.2125
=-0.91 %

where

Note: The Operating Income data used here is four times the quarterly (Oct. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quest PharmaTech  (TSXV:QPT) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Quest PharmaTech's WACC % is 1.00%. Quest PharmaTech's ROIC % is -1.51% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Quest PharmaTech ROIC % Related Terms

Thank you for viewing the detailed overview of Quest PharmaTech's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Quest PharmaTech (TSXV:QPT) Business Description

Traded in Other Exchanges
N/A
Address
8123 Roper Road NW, Edmonton, AB, CAN, T6E 6S4
Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.
Executives
Ragupathy Madiyalakan Director

Quest PharmaTech (TSXV:QPT) Headlines

No Headlines